Norges Bank’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Norges Bank’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-415,776	Closed	-$31.3M	–	2159
2022 Q2	$31.3M	Buy	415,776 +46,993	+13%	+$2.09M	0.01%	1010
2022 Q1	$9.9M	Buy	368,783 +34,000	+10%	+$1.14M	﹤0.01%	1705
2021 Q4	$16M	Hold	334,783	–	–	﹤0.01%	1579
2021 Q3	$22.2M	Sell	334,783 -6,171	-2%	-$440K	﹤0.01%	1424
2021 Q2	$26.6M	Buy	340,954 +8,624	+3%	+$637K	0.01%	1361
2021 Q1	$31.4M	Sell	332,330 -65,388	-16%	-$7.78M	0.01%	1270
2020 Q4	$48.5M	Buy	397,718 +63,982	+19%	+$7.01M	0.01%	990
2020 Q3	$29.2M	Buy	333,736 +52,595	+19%	+$3.66M	0.01%	1177
2020 Q2	$18.2M	Buy	281,141 +22,201	+9%	+$1.28M	0.01%	1493
2020 Q1	$11.6M	Buy	+258,940	New	+$13.8M	﹤0.01%	1551

Norges Bank's TPTX Position: Q3 2022 in Review

Norges Bank sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 415,776 shares — an estimated $31.3M sold.

Norges Bank first reported a position in TPTX in Q1 2020 and held it in 10 quarters. The position peaked at $48.5M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Norges Bank reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Norges Bank sold 415,776 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $31.3M.
Norges Bank first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2020 and held it in 10 quarters.
Norges Bank's Turning Point Therapeutics, Inc. Common Stock position peaked at $48.5M in Q4 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Norges Bank's 13F filing for Q3 2022, filed 14 Nov 2022.